Pegylated liposomal doxorubicin in combination with hyperthermia in the treatment of a case of advanced hepatocellular carcinoma.

J Clin Gastroenterol. 2002 Jan;34(1):96-8.

Dvorák JZoul ZMelichar BJandík PMergancová JMotycková IKalousová DPetera J.

Source

Department of Oncology and Radiotherapy, Charles University Medical School & Teaching Hospital, Hradec Králové, Czech Republic. dvorakj@fnhd.cz

Abstract

BACKGROUND:

Currently, there is no standard treatment of inoperable advanced hepatocellular carcinoma.

STUDY:

A patient with advanced hepatocellular carcinoma was treated with intravenous infusion of pegylated liposomal doxorubicin (PLD, Caelyx) in combination with ultrasound hyperthermia of the liver. Each cycle consisted of infusion of 60 mg of PLD followed by two fractions of hyperthermia 41 degrees C to 43 degrees C for 45 minutes 1 and 48 hours after infusion, respectively.

RESULTS:

A substantial regression of the tumor was observed on computed tomography scans. No toxicity of combined treatment was noted.

CONCLUSIONS:

This may be the first report of the combination of PLD and hyperthermia in the treatment of advanced hepatocellular carcinoma. Our observation suggests that the combination of PLD with hyperthermia is technically feasible, well tolerated, and could have synergistic potential.

Dvorák-2002-Pegylated Liposomal Doxorubicin In
Dvorák-2002-Pegylated Liposomal Doxorubicin In
Dvorák-2002-Pegylated liposomal doxorubicin in.pdf
405.8 KiB
1266 Downloads
Details